The phosphorus in plasma is present almost entirely as inorganic phosphate (Pi) and renal handling of Pi plays a major role in regulating the plasma level of Pi. About 95% of plasma Pi is ultrafilterable at the glomerulus and, under normal conditions, about 20% of the filtered Pi is excreted in the urine. Secretion of Pi does not appear to be an important transport process in the mammalian kidney. The convoluted and straight segments of the proximal tubule are the major nephron sites where filtered Pi is reabsorbed. Reabsorption in the proximal tubule is a saturable process, and the Tm is influenced by the prevailing metabolic and
hormonal conditions [1] . The peptide hormones that influence renal Pi handling exert their effects primarily by changing Pi reabsorption in the proximal tubule. The initial, probably ratelimiting, step in Pi reabsorption is entry into the proximal tubule cell through the action of a Na/Pi cotransport system in the apical brush border membrane (BBM). The efflux (and influx) step across the basolateral membrane is less well-defined and more than one transport mechanism may be involved. The evidence for these steps in transcellular transport has been reviewed recently [2, 3] . Regulation of tubular reabsorption of Pi by many different factors appears to be accomplished, at least in part, through changes in the Na/Pi cotransport capacity of the apical BBM. This review is focused on the regulation of this step by peptide hormones and growth factors ( Table 1 ).
Stimulation of Na/Pi cotransport
Insulin There are insulin receptors in the basolateral membrane of the proximal tubule [4] . A direct stimulatory effect of insulin on the renal Na/Pi cotransporter was demonstrated in vitro by incubation of proximal tubule segments from canine kidney with physiological concentrations of insulin, followed by preparation of BBM vesicles for direct assessment of Na/Pi cotransport [5] . These findings were complemented by studies in vivo that used somatostatin infusion to depress plasma insulin levels in rats. Somatostatin increased Pi delivery to the late proximal tubule and increased Pi excretion [6] . This was independent of parathyroid hormone (PTH) and other consequences of somatostatin action, and suggested a role for endogenous insulin in regulating Na/Pi cotransport. There is evidence that insulin also might be involved in the up-regulation of renal Na/Pi cotransport in response to acute Pi deprivation. This was suggested by the discovery of a transient increase in plasma insulin after rats were given a low Pi meal [7] . Further in vivo studies showed that the established © 1996 by the International Society of Nephrology up-regulatory response of the rat renal Na/Pi cotransporter to Pi deprivation was not maintained during subsequent induction of a diabetic state [8] . A complementary approach [9] showed that the renal Na/Pi cotransporter in diabetic rats was not up-regulated by subsequent Pi deprivation, but the adaptation was restored by exogenous insulin. Preliminary data from Western blots (Kempson, Murer and Biber, unpublished observations) indicate that the increased abundance of Na/Pi cotransporter protein in the BBM of Pi deprived rats [10] did not occur in the Pi-deprived diabetic rats but was restored by insulin treatment. Thus the Na/Pi cotransport activity correlated with the abundance of Na/Pi cotransporter protein in the BBM. Although insulin has a direct action on the Na/Pi cotransporter in an in vitro setting, both in proximal tubules and cultured OK cells [5, 11, 12] , it remains to be determined if the apparent insulin-dependence of the up-regulation of Na/Pi cotransport during Pi deprivation is due to a renal action of insulin or if it is an indirect effect of other actions of insulin, such as prevention of the hyperglycemia present in diabetic rats. It is interesting to note that both the direct stimulatoiy effect of insulin on Na/Pi cotransport in OK cells and the acute adaptive increase in renal Na/Pi cotransport during Pi deprivation, do not require de novo protein synthesis [11, 13] .
Growth hormone and insulin-like growth factor (IGF)-1 Chronic administration of growth hormone to dogs increased tubular Pi reabsorption independently of PTH [14] , an effect shown subsequently to be accompanied by specific stimulation of the Na/Pi cotranporter in the BBM [15] . Suppression of growth hormone secretion in immature rats decreased the tubular capacity for Pi reabsorption [16] . There are receptors for growth hormone in the renal proximal tubule that lead to activation of phospholipase C [17] , but Pi transport is not regulated acutely by growth hormone [18] . The chronic action of growth hormone is probably mediated by IGF-1. Renal production of IGF-1 is stimulated by growth hormone and IGF-1 receptors are present in the basolateral membrane of proximal tubule cells [19] . Chronic administration of IGF-1 to hypophysectomized rats stimulated the tubular capacity for Pi reabsorption and the effect did not involve PTH. This action of IGF-1 was accompanied by specific stimulation of the Na/Pi cotransporter in the BBM [20] , similar to growth hormone action in dogs [14] . Direct addition of IGF-1 to microperfused rabbit proximal tubules produced specific stimulation of phosphate transport [18] and incubation of OK cells with IGF-1 also stimulated Na/Pi cotransport [21] . The stimulatory effect in OK cells produced an increase in the Vm and required de novo protein synthesis. The IGF-1 concentrations were much lower than those required for stimulation by insulin, suggesting that IGF-1 action was not mediated by insulin receptors (21] . Further studies in OK cells suggested a role for tyrosine phosphoiylation in mediating changes in Na/Pi cotransport. Vanadate increased tyrosine kinase activity and stimulated Na/Pi cotransport, while in contrast, genistein decreased tyrosine kinase and inhibited Na/Pi cotransport. These effects were dose-dependent and there was a close correlation between the activities of tyrosine kinase and Pi transport [221. Since the receptor for IGF-1 activates an intrinsic tyrosine kinase, the possibility exists that IGF-1 modulates Pi transport at the cellular level by an intracellular pathway that involves protein tyrosine phosphorylation. It is not known if the end result of this pathway is to increase the abundance of Na/Pi cotransporters in the renal BBM.
Inhibition of Na/Pi cotransport Calcitonin Pharmacological doses of calcitonin increase Pi excretion in rats but this effect could be due, in part, through release of PTH in response to the hypocalcemia. A direct effect to decrease the tubular capacity for Pi reabsorption was demonstrated in thyroparathyroidectomized (TPTX) rats [23] and the proximal tubule is the primary site of action [24] . Inhibition of Pi transport in the rat proximal tubule is probably mediated by specific inhibition of the Na/Pi cotransporter in the apical BBM [25] . Since calcitonin does not stimulate adenylate cyclase in microdissected proximal tubules [2] , the inhibition of Na/Pi cotransport is unlikely mediated by cyclic AMP. The role of calcitonin in Pi homeostasis is unclear because changes in endogenous secretion of calcitonin do not produce consistent changes in Pi metabolism. The principle action of calcitonin may be on bone and its primary physiological role in the kidney may be to conserve calcium and magnesium.
A trial natriuretic peptide
In the absence of endogenous PTH, infusion of atrial natriuretic peptide (ANP) increases Pi excretion in both rats and dogs [1, 2] . In BBM vesicles from the ANP-treated rats there was decreased Na/Pi cotransport and decreased Na/H exchange but no change in other Na-dependent transporters [26, 271. A similar trend was observed in OK cells following incubation with ANP and both effects were reproduced by 8-bromo-cyclic GMP, suggesting that cyclic GMP may be an intracellular mediator [21. The response of Na/cotransport systems to ANP infusion in vivo may he mediated indirectly through stimulation of intrarenal dopamine production in response to ANP [28] .
Epidermal growth factor
The mouse kidney is a major site of synthesis of the epidermal growth factor (EGF) precursor [29] and several segments of the rabbit nephron, including the convoluted and straight segments of the proximal tubule, have EGF receptors [30] . EGF has direct effects on several renal cell functions [311 including stimulation of Pi transport in perfused proximal tubules from rabbit kidney [32] . This effect was reproduced in cultured renal epithelial LLC-PK1 cells [33] but not in OK cells where EGF (10 ng/ml) inhibited Na/Pi cotransport [31, 34] . The response to EGF in both cell lines required incubations of 18 to 24 hours. The inhibitory response in OK cells involved a decreased Vmax, was blocked by inhibitors of RNA and protein synthesis and phospholipase C activity, and was accompanied by a two-to threefold decrease in abundance of the Na/Pi cotransporter specific mRNA [31] . EGF may induce synthesis of a regulatory protein that inhibits the synthesis and/or intracellular processing of the Na/Pi cotransporter. EGF action was not dependent on cyclic AMP or prostaglandin E2 [34] but may be due to activation of the catalytic activity of phospholipase C-yl by the tyrosine kinase activity of the EGF receptor [35] .
Increased activity of phospholipase C-yl leads ultimately to activation of protein kinase C. The opposing effects of EGF in LLC-PK1 and OK cells results from the fact that activation of protein kinase C stimulates Na/Pi cotransport in the former and inhibits it in the latter cell line [31] . EGF stimulation of Pi transport in rabbit proximal tubules was much more rapid (within 30 mm) compared to the established cell lines and the stimulation was blocked by inhibitors of tyrosine kinase and protein kinase C [36] .
Transforming growth factors
During malignancy-associated hypercalcemia there may be decreased tubular reabsorption of Pi and hypophosphatemia.
These changes may be due in part to tumor-produced circulating factors that directly decrease renal Pi transport. One of these factors is transforming growth factor (TGF)-a which produces an increase in plasma calcium when injected into mice [37] . TGF-a stimulates bone resorption and has been implicated in malignancy-associated hypercalcemia [34] . Incubation of OK cells with TGF-a (10 ng/ml) for 24 hours decreased Na/Pi cotransport by 35% [34] . The effects were time and dose-dependent and were independent of cyclic AMP and prostaglandin E2 synthesis. These responses are similar to the effects of EGF on OK cells (above) and this may arise because the two polypeptides may share a common receptor [38] .
TGF-/3 is expressed in tumor cell lines and in normal tissues of the mouse and is present in plasma in a protein-bound form [39] . It suppresses proliferation of cultured proximal tubule cells from rabbit kidney and promotes type I collagen production by rat kidney epithelial cells [39] . High affinity receptors for TGF-/3 are present in glomerular and epithelial cells of mouse kidney [40] . Incubation of OK cells with TGF-p (3 ng/ml) produced specific inhibition of Na/Pi cotransport within eight hours and the effect was maximum at 18 hours when there was 50% inhibition of Pi uptake [391. The inhibition was dependent on RNA and protein synthesis but was independent of cyclic AMP, prostaglandin E2 synthesis, pertussis toxin-sensitive G proteins and protein kinase C. It has been speculated that circulating TGF-p, like TGF-a, might contribute to the hyphophosphatemia in malignancy-associated hypercalcemia, but this is unclear at present.
Parathyroid hormone-related protein (PTHrP)
PTHrP is the major mediator of the hypercalcemia, phosphatuna and hypophosphatemia of malignancy-associated hypercalcemia [41] . At the amino terminus there is marked homology between PTH and PTHrP so that they bind with equal affinity to identical receptors in the kidney. Thus PTHrP in vivo, in the absence of PTH, increases renal tubular reabsorption of calcium, decreases Pi reabsorption, and increases nephrogeneous cyclic AMP [2, 41] . Direct addition of the ito 34 fragment of PTHrP to OK cells stimulated cyclic AIvIP production and specifically inhibited Na/Pi cotransport with a time-and dose-dependency identical to PTH [42] . Pretreatment of OK cells with TGF-a blunted the rise in cyclic AMP due to either PTH or PTHrP. Furthermore, the inhibition of Na/Pi cotransport by TGF-x or EGF was not increased further by subsequent addition of P11-I or PTHrP [34] . It is possible that EGF produced in the kidney or TGF-a from a renal tumor might modulate, via EGF receptors, the response of renal cells to PTH or PTHrP. However, the physiological significance of these interactions observed in cultured cells remains to be determined. It has been suggested [34, 39] that TGF-a and TGF-13 may mediate the phosphaturia observed in cases of malignant hypercalcemia where there is no accompanying increase in urinary cyclic AMP.
Parathyroid hormone
The phosphaturic action of parathyroid hormone (PTH) has been studied extensively and is due primarily to inhibition of Pi reabsorption in the proximal tubule [1] [2] [3] . The straight segment may be important for final regulation of Pi excretion by PTH, especially in the rabbit [1] . PTH-induced inhibition of the Na/Pi cotransporter in the apical BBM involves a decreased Vmax [15] and probably accounts for the decrease in tubular Pi reabsorption. PTH binds to specific receptors on the basolateral membrane [2] and activates both the adenylate cyclase/protein kinase A system and the phopholipase C/protein kinase C system. The rise in intracellular calcium associated with the latter does not appear to be directly involved in regulating Na/Pi cotransport. However, there is considerable evidence that both protein kinase A-and protein kinase C-dependent phosphorylation are important for PTH-induced inhibition of Na/Pi cotransport. It is not yet known if different subpopulations of PTH receptors are coupled to the two intracellular pathways or if the Na/Pi cotransporter is phosphorylated when the pathways are activated by PTH binding. This work has been reviewed in detail recently [2, 3] and will not be discussed here.
Collaborative efforts between several laboratories have focused on determining if the net result of PTH action, regardless of the signal pathway, is a decrease in the abundance of the Na/Pi cotransporter in the BBM. The progress of this work was greatly facilitated by the availability of new tools as a result of the recent cloning of the rat renal Na/Pi cotransporter (NaPi-2) [43] . The possibility that PTH might promote endocytic removal of NaPi-2 was raised by the observation that colchicine, a microtubule poison, blocked the phosphaturic action of PTH in rats [44] . More direct evidence that PTH action on Na/Pi cotransport may be mediated in part by endocytosis was obtained in OK cells. PTH action on Na/Pi cotransport was significantly impaired when endocytosis was inhibited [45] . Subsequent data from PTHtreated rats provided further support for this idea. The Nadependent Pi-protectable binding of phosphonoformic acid, a specific inhibitor of Na,Pi cotransport, was decreased in BBMV from PTH-treated rats compared to controls. This was due to a decrease in the binding capacity rather than the affinity [46] and is consistent with the Vma,, change in Na/Pi cotransport [15] . Addi-tional work in OK cells has shown that the onset of PTH action on Na/Pi cotransport does not require de novo protein synthesis but the recovery step, after PTH removal, is protein synthesis-dependent [47] . This leads to the conclusion that the Na/Pi cotransporter, once internalized, is probably degraded and not recycled by exocytosis to the plasma membrane. Recovery from PTH action will require synthesis of new transporters and trafficking to the plasma membrane. Incubation of OK cells with PTH, under conditions that inhibited plasma membrane Na/Pi cotransport (Vmax effect), did not change total endocytic activity [48] . It was proposed that PTH must stimulate selective removal of Na/Pi cotransporters without changing the overall rate of constitutive endocytosis. One possible role of the protein phosphorylation pathways may be to phosphorylate the Na/Pi cotransporter so that the attached Pi serves to label and/or inactivate it for shuttling into areas where endocytic vesicles are being formed. Several potential phosphorylation sites are present in the cytoplasmic domains of the deduced amino acid sequence of NaPi-2 [43] .
A polyclonal antibody to NaPi-2 proved to be invaluable for further studies. Preliminary work with flow cytometry has detected specific binding of the antibody to a non-denatured fraction of light endosomes [49] that represents true intracellular endosomal vesicles [50] . There was no specific binding to non-denatured BBM, presumably because antigenic sites are on the inside surface of BBM vesicles and are only exposed by denaturation. Thus the binding to light endosomes indicates the presence of a true intracellular pool of NaPi-2 that cannot be attributed to BBM contamination of the endosomal preparation. Use of the antibody for Western blots of denatured BBM has shown unequivocally that the NaPi-2 abundance in BBM of parathyroidectomized (PTX) rats was decreased by a one to two hour treatment with PTH at a dose that inhibited Na/Pi cotransport [51 and LOtscher et al, this issue]. The loss of NaPi-2 from the BBM was observed in proximal tubules throughout the cortex, both superficial and juxtamedullaiy, but there was no change in immunofluorescence specific for y-glutamyltranspeptidase, a BBM marker enzyme.
Only a limited amount of intracellular NaPi-2 was detected by the immunohistochemical technique, lending support to the notion that internalized NaPi-2 may be rapidly degraded. Taken together, these findings strongly suggest that one mechanism by which PTH inhibits renal Na/Pi cotransport at the cellular level involves endocytic removal of Na/Pi cotransporters from the BBM of the renal proximal tubule.
Conclusions
Plasma Pi is maintained within a narrow range, and since the kidney plays a major role in Pi homeostasis it is perhaps not surprising that many different factors regulate renal Pi transport. Extrapolation of data from cultured OK cells to the intact animal may not always be justified. The true physiological role of several peptides that inhibit Na/Pi cotransport in OK cells remains to be determined. None of the peptides discussed here has a primary role as a regulator of renal Pi transport. A true Pi regulating hormone has not been identified, although there has been a recent report of heat-labile factor produced by tumor-induced osteomalacia [52] . PTH remains the best characterized peptide hormone in terms of the intracellular signals involved and the cellular response. As work proceeds on understanding PTH action, the findings may shed light on the mechanism of action of other physiological regulators of renal Pi transport.
